Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck

VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a market worth $8 billion.